Nicox's Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected

Press ReleaseNicox's Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than ExpectedConfirms topline results expected to be reported Q3 2025NCX 470 demonstrated robust efficacy and safety in topline results from first Phase 3 trial, Mont BlancNCX 470 partnering efforts will focus on routes for bringing the product to market in the U.S.Results from the NCX 470 Phase 3b Whistler Mechanism of Action trial expected in Q1 2025December 2, 2024 –...

Biot, 02/12/2024 (informazione.news - comunicati stampa - salute e benessere)

Attachment